Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial

The optimal antithrombotic treatment after percutaneous coronary intervention (PCI) with stenting in patients with atrial fibrillation (AF) is unknown. In the ENGAGE AF-TIMI 48 trial, edoxaban was noninferior to a vitamin K antagonist (VKA) with respect to the prevention of stroke or systemic emboli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2018-02, Vol.196, p.105-112
Hauptverfasser:	Vranckx, Pascal, Lewalter, Thorsten, Valgimigli, Marco, Tijssen, Jan G., Reimitz, Paul-Egbert, Eckardt, Lars, Lanz, Hans-Joachim, Zierhut, Wolfgang, Smolnik, Rüdiger, Goette, Andreas
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetylsalicylic acid Administration, Oral Angioplasty Anticoagulants Antiplatelet therapy Atrial Fibrillation - diagnostic imaging Atrial Fibrillation - drug therapy Atrial Fibrillation - mortality Bleeding Cardiac arrhythmia Cerebral infarction Clinical trials Clopidogrel Complications Drug Therapy, Combination Embolism Evaluation Female Fibrillation Fibrinolytic Agents - administration & dosage Humans Implants Internationality Intervention Ischemia Male Myocardial infarction Patient Safety Patients Percutaneous Coronary Intervention - adverse effects Percutaneous Coronary Intervention - methods Postoperative Complications - prevention & control Pyridines - therapeutic use Randomization Risk Assessment Safety Single-Blind Method Stents Strategy Stroke Surgical implants Survival Rate Therapy Thiazoles - therapeutic use Thromboembolism Thrombosis Treatment Outcome Vitamin K
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!